Gelesis Holdings (Gelesis Holdings) Gross Margin % : 55.01% (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Gelesis Holdings Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Gelesis Holdings's Gross Profit for the three months ended in Jun. 2023 was $0.61 Mil. Gelesis Holdings's Revenue for the three months ended in Jun. 2023 was $1.11 Mil. Therefore, Gelesis Holdings's Gross Margin % for the quarter that ended in Jun. 2023 was 55.01%.

The historical rank and industry rank for Gelesis Holdings's Gross Margin % or its related term are showing as below:

GLSHQ' s Gross Margin % Range Over the Past 10 Years
Min: -61.4 Med: 1.9 Max: 10.75
Current: -61.4

During the past 2 years, the highest Gross Margin % of Gelesis Holdings was 10.75%. The lowest was -61.40%. And the median was 1.90%.

GLSHQ's Gross Margin % is not ranked
in the Biotechnology industry.
Industry Median: 59.43 vs GLSHQ: -61.40

Gelesis Holdings had a gross margin of 55.01% for the quarter that ended in Jun. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Gelesis Holdings was 0.00% per year.

Gelesis Holdings Gross Margin % Historical Data

The historical data trend for Gelesis Holdings's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gelesis Holdings Gross Margin % Chart

Gelesis Holdings Annual Data

Trend

Dec21

Dec22

Gross Margin %

10.75

-6.95

Gelesis Holdings Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Gross Margin %	Get a 7-Day Free Trial					46.66	45.64	-441.97	29.44	55.01

Competitive Comparison of Gelesis Holdings's Gross Margin %

For the Biotechnology subindustry, Gelesis Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gelesis Holdings's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gelesis Holdings's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Gelesis Holdings's Gross Margin % falls into.

Gelesis Holdings Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Gelesis Holdings's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )	=	Gross Profit (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-1.8	/	25.767
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(25.767 - 27.558)	/	25.767
	=	-6.95 %

Gelesis Holdings's Gross Margin for the quarter that ended in Jun. 2023 is calculated as

Gross Margin % (Q: Jun. 2023 )	=	Gross Profit (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	0.6	/	1.107
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(1.107 - 0.498)	/	1.107
	=	55.01 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Gelesis Holdings (OTCPK:GLSHQ) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Gelesis Holdings had a gross margin of 55.01% for the quarter that ended in Jun. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Gelesis Holdings Gross Margin % Related Terms

Thank you for viewing the detailed overview of Gelesis Holdings's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gelesis Holdings (Gelesis Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gelesis Holdings Inc (OTCPK:GLSHQ) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

501 Boylston Street, Suite 6102, Boston, MA, USA, 02116

Website

https://www.gelesis.com

Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.

Executives

Raju S Kucherlapati	director	77 LOUIS PASTEUR AVENUE, BOSTON MA 02115
Bomsmaster Llc	10 percent owner	195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510
Paul R. Fonteyne	director	C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Hpso Spv Ltd	10 percent owner	SARNIA HOUSE, LE TRUCHOT, ST PETER PORT Y7 GY1 4NA
Alessandro Sannino	officer: Lead Project Scientist	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Dominic Perks	director	GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON NY 02116
David A. Pass	officer: Chief Op. & Comm. Officer	GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON MA 02116
Elaine Chiquette	officer: Chief Scientific Officer	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Jane Wildman	director	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Harry L. Leider	officer: Chief Medical Officer	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Clayton Christopher	director	2407 S. CONGRESS AVE, SUITE E103, AUSTIN TX 78704
Health Plc Puretech	10 percent owner	6 TIDE STREET, SUITE 400, BOSTON MA 02210
Ssd2, Llc	10 percent owner	142 TEMPLE STREET, SUITE 206, NEW HAVEN CT 06511
Yishai Zohar	director, officer: President & CEO	C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Elon Boms	10 percent owner	C/O THIMBLE POINT ACQUISITION CORP., 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510